DnaJC7 specifically regulates tau seeding
- The University of Texas Southwestern Medical Center, United States
Abstract
Neurodegenerative tauopathies are caused by accumulation of toxic tau protein assemblies. This appears to involve template-based seeding events, whereby tau monomer changes conformation and is recruited to a growing aggregate. Several large families of chaperone proteins, including Hsp70s and J domain proteins (JDPs) cooperate to regulate the folding of intracellular proteins such as tau, but the factors that coordinate this activity are not well known. The JDP DnaJC7 binds tau and reduces its intracellular aggregation. However, it is unknown whether this is specific to DnaJC7 or if other JDPs might be similarly involved. We used proteomics within a cell model to determine that DnaJC7 co-purified with insoluble tau and colocalized with intracellular aggregates. We individually knocked out every possible JDP and tested the effect on intracellular aggregation and seeding. DnaJC7 knockout decreased aggregate clearance and increased intracellular tau seeding. This depended on the ability of the J domain (JD) of DnaJC7 to stimulate Hsp70 ATPase activity, as JD mutations that block this interaction abrogated the protective activity. Disease-associated mutations in the JD and substrate binding site of DnaJC7 also abolished its protective activity. DnaJC7 thus specifically regulates tau aggregation in cooperation with Hsp70.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting file. Source Data files for included Western Blot images are provided as Figure 1 - Supplement 1 - Source Data 1, Figure 2 - Supplement 1 - Source Data 1, Figure 3 -Supplement 1 - Source Data 1, and Figure 5 - Supplement 1 - Source Data 1. Source data files have been provided for Figures 1 (Source Data 1 and 2) and 2 (Source Data 3) on Dryad at: https://doi.org/10.5061/dryad.fj6q57402FCS files are deposited on Cytobank at: https://community.cytobank.org/cytobank/projects/1505
-
DnaJC7 specifically regulates tau seedingDryad Digital Repository, doi:10.5061/dryad.fj6q57402.
Article and author information
Author details
Barbara Elena Stopschinski
Charles L White III
Lukasz A Joachimiak
Funding
National Institute on Aging (RF1AG078888)
- Valerie Ann Perez
- Vishruth Mullapudi
- Lukasz A Joachimiak
National Institute on Aging (3R01AG048678)
- Valerie Ann Perez
- David W Sanders
- Ayde Mendoza-Oliva
- Barbara Elena Stopschinski
- Marc I Diamond
National Institute on Aging (1RF1AG059689)
- Valerie Ann Perez
- David W Sanders
- Ayde Mendoza-Oliva
- Barbara Elena Stopschinski
- Charles L White III
- Marc I Diamond
National Institute on Aging (1RF1AG065407)
- Valerie Ann Perez
- David W Sanders
- Ayde Mendoza-Oliva
- Barbara Elena Stopschinski
- Vishruth Mullapudi
- Lukasz A Joachimiak
- Marc I Diamond
McCune Foundation
- Charles L White III
Winspear Family Center for Research on the Neuropathology of Alzheimer's Disease
- Charles L White III
Chan Zuckerberg Initiative (2018-191983)
- Charles L White III
- Lukasz A Joachimiak
- Marc I Diamond
Chan Zuckerberg Initiative (2021-237348)
- Charles L White III
- Lukasz A Joachimiak
- Marc I Diamond
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2023, Perez et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,128
- views
-
- 176
- downloads
-
- 7
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
DnaJC7 specifically regulates tau seeding
eLife 12:e86936.
https://doi.org/10.7554/eLife.86936
Further reading
-
- Biochemistry and Chemical Biology
Identifying target proteins for bioactive molecules is essential for understanding their mechanisms, developing improved derivatives, and minimizing off-target effects. Despite advances in target identification (target-ID) technologies, significant challenges remain, impeding drug development. Most target-ID methods use cell lysates, but maintaining an intact cellular context is vital for capturing specific drug–protein interactions, such as those with transient protein complexes and membrane-associated proteins. To address these limitations, we developed POST-IT (Pup-On-target for Small molecule Target Identification Technology), a non-diffusive proximity tagging system for live cells, orthogonal to the eukaryotic system. POST-IT utilizes an engineered fusion of proteasomal accessory factor A and HaloTag to transfer Pup to proximal proteins upon directly binding to the small molecule. After significant optimization to eliminate self-pupylation and polypupylation, minimize depupylation, and optimize chemical linkers, POST-IT successfully identified known targets and discovered a new binder, SEPHS2, for dasatinib, and VPS37C as a new target for hydroxychloroquine, enhancing our understanding these drugs’ mechanisms of action. Furthermore, we demonstrated the application of POST-IT in live zebrafish embryos, highlighting its potential for broad biological research and drug development.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib, and Pirtobrutinib have been clinically approved. All are covalent active site inhibitors, with the exception of the reversible active site inhibitor Pirtobrutinib. The large number of available inhibitors for the BTK target creates challenges in choosing the most appropriate BTKi for treatment. Side-by-side comparisons in CLL have shown that different inhibitors may differ in their treatment efficacy. Moreover, the nature of the resistance mutations that arise in patients appears to depend on the specific BTKi administered. We have previously shown that Ibrutinib binding to the kinase active site causes unanticipated long-range effects on the global conformation of BTK (Joseph et al., 2020). Here, we show that binding of each of the five approved BTKi to the kinase active site brings about distinct allosteric changes that alter the conformational equilibrium of full-length BTK. Additionally, we provide an explanation for the resistance mutation bias observed in CLL patients treated with different BTKi and characterize the mechanism of action of two common resistance mutations: BTK T474I and L528W.
